Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nadia Diclemente

Physician Assistant Pittsburgh, PA Physician Assistant

NPI 1043648058 CMS profile 11241088

1 Childrens Hospital Dr, 4401 Penn Avenue, Pittsburgh, PA 15224

Open in the dashboard

General payments

$7,278

595 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nadia Diclemente of Pittsburgh, PA is reported in the CMS Open Payments database as having received $7,278 across 595 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,220 86
2024 General $1,624 143
2023 General $2,257 204
2022 General $1,494 117
2021 General $683 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadia Diclemente
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nadia Diclemente were reported at $1,220. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nadia Diclemente Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $683 $132 $37–$438 $132
2022 $1,494 $155 $48–$522 $149
2023 $2,257 $167 $52–$557 $160
2024 $1,624 $178 $55–$600 $164
2025 $1,220 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,638 176 payments
  2. Janssen Biotech, Inc. $1,307 137 payments
  3. Galderma Laboratories, L.P. $1,117 114 payments
  4. Genzyme Corporation $914 48 payments
  5. Regeneron Healthcare Solutions, Inc. $438 14 payments
  6. E.R. Squibb & Sons, L.L.C. $405 36 payments
  7. Novartis Pharmaceuticals Corporation $324 16 payments
  8. Journey Medical Corporation $169 4 payments
  9. Biofrontera Inc. $150 10 payments
  10. Revance Therapeutics, Inc. $130 4 payments
  11. Other $687 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,973 589 payments
  2. Education $306 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,396 70 payments
  2. SKYRIZI $865 110 payments
  3. TREMFYA $832 81 payments
  4. RINVOQ $601 54 payments
  5. AKLIEF $519 59 payments
  6. SIMPONI ARIA $482 57 payments
  7. STELARA $482 57 payments
  8. SIMPONI $482 57 payments
  9. REMICADE $475 56 payments
  10. EPSOLAY $464 53 payments
  11. Other $3,826 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

548

Median for Physician Assistant: 241

Drug cost

$13,962

Median for Physician Assistant: $4,110

Branded share of claims

5.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 100 $4,452
Fluorouracil Generic 47 $3,580
Ketoconazole Generic 101 $1,514
Clindamycin Phosphate Generic 33 $1,470
Triamcinolone Acetonide Generic 110 $890
Metronidazole Generic 12 $881
Doxycycline Hyclate Generic 31 $319
Methotrexate Methotrexate Sodium Brand 13 $243
Valacyclovir Valacyclovir Hcl Brand 17 $238
Minoxidil Generic 45 $210

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$43,619

Of which drugs: $5,772

Medicare patients

366

Average age 73

Services billed

5,252

200 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 49%
Ischemic heart disease 20%
Diabetes 19%
Depression 18%
Osteoporosis 18%
Cancer 17%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 15 4,400 $5,762

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $289
$289 — —
TREMFYA
  • Janssen Biotech, Inc. $282
$282 — —
DUPIXENT
  • GENZYME CORPORATION $239
  • Regeneron Healthcare Solutions, Inc. $28
$267 — —
RINVOQ
  • AbbVie, Inc. $165
$165 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

595 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record